secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265937
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest reports Q3 net loss $3.5M, cash $7.5M; continues strategic alternatives process
--------------------------------------------------------------------------------

- Cash and equivalents $7.5M at Sept 30, 2025, down from $30.3M at Dec 31, 2024.
- Net loss Q3 2025: $3.5M ($0.79/share) vs $10.6M ($5.32/share) in Q3 2024.
- R&D expenses fell to $0.6M from $7.6M due to reprioritizing toward strategic alternatives.
- Company continues strategic alternatives process to maximize stockholder value.
- Expects start of TPST-1495 Phase 2 in collaboration with NCI and Cancer Prevention Clinical Trials Network.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/0001193125-25-265937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312525265937/tpst-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer